The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

Westpac cops $3.64m penalty for lender responsibility breaches
Finance

Westpac cops $3.64m penalty for lender responsibility breaches

Credit Contracts and Consumer Finance Act in focus again.

Andy Macdonald 28 Nov 2025
RBNZ staff thin on ground after asbestos reopen
Finance

RBNZ staff thin on ground after asbestos reopen

The finance minister understands the new flexible working policy for the RBNZ is near.

Andy Macdonald 28 Nov 2025
Scam protection at heart of Code of Banking Practice update
Finance

Scam protection at heart of Code of Banking Practice update

Compensation is on the cards if banks fail all five scam-protection commitments.

Andy Macdonald 28 Nov 2025
RBNZ data scotches Dosh claims of bank registration application
Finance

RBNZ data scotches Dosh claims of bank registration application

The regulator received no bank-registration applications in July 2024. 

Andy Macdonald 27 Nov 2025